9MW1411

9MW1411 is a **humanized monoclonal antibody** that targets **Staphylococcus aureus alpha-toxin (toxA)**. It is being developed as an anti-infective and antibacterial therapeutic agent, specifically as a bacterial toxin inhibitor. Its primary indication is for the treatment of acute bacterial skin and skin structure infections (ABSSSI) caused by S. aureus, including in combination with standard antimicrobial drugs. Clinical studies have shown that 9MW1411 is safe and well-tolerated in healthy subjects at single intravenous doses up to 5000 mg, with a long elimination half-life of 19–23 days. Its mechanism of action involves neutralizing the S. aureus alpha-toxin, thereby mitigating the pathogenic effects and promoting recovery from infection. The drug is a new molecular entity and is currently the subject of Phase 2 clinical trials[1][2][5][7].

Other names

9MW1411MW14MW-14MW 14